SCHEMBL20780402

SCHEMBL20780402

CCC(=O)CCCC(=O)N1CCOCC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLA P06280 2/20 0.63
▸ L3MBTL1 Q9Y468 4/20 0.62
▸ RAB9A P51151 3/20 0.62
▸ POLB P06746 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ TSHR P16473 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.53
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ ATM Q13315 1/20 0.48
▸ NPC1 O15118 2/20 0.46
▸ USP2 O75604 1/20 0.46
▸ FKBP1A P62942 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ HTT P42858 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22414035 0.89 TSHR (0.62) GLAL3MBTL1RAB9APOLBLMNA
SCHEMBL253804 0.83 GLA (0.64) GLAL3MBTL1RAB9APOLBLMNA
SCHEMBL9415751 0.82 GLA (0.67) GLAL3MBTL1RAB9APOLBLMNA
SCHEMBL27922265 0.81 GLA (0.67) GLAL3MBTL1RAB9APOLBLMNA
SCHEMBL2718359 0.81 L3MBTL1 (0.69) GLAL3MBTL1RAB9APOLBLMNA
SCHEMBL7101454 0.81 L3MBTL1 (0.66) GLAL3MBTL1RAB9APOLBLMNA
SCHEMBL19574225 0.81 ATM (0.75) GLAL3MBTL1RAB9APOLBLMNA
SCHEMBL7694058 0.81 GLA (0.65) GLAL3MBTL1RAB9APOLBLMNA
SCHEMBL8973067 0.80 L3MBTL1 (0.67) GLAL3MBTL1RAB9APOLBLMNA
SCHEMBL8973343 0.80 L3MBTL1 (0.67) GLAL3MBTL1RAB9APOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020030814-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2020-02-13 — — WO disclosed
WO-2019043018-A1 METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) 2019-03-07 — — WO disclosed
Send feedback